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Atrial fibrillation (AF) constitutes a major risk factor for stroke and death.1,2 At present, the risk for stroke and the 
indication for anticoagulant treatment in AF can be estimated 
by clinical risk factors, eg, the CHADS2 or the later developed 
CHA2DS2VASc score (which assigns 1 point each for a his-
tory of congestive heart failure, hypertension, diabetes melli-
tus, vascular disease, age ≥65 years, and sex category [female 
sex], and 2 points for age ≥75 years and previous stroke/
Background—High-sensitivity troponin-I (hs-TnI) measurement improves risk assessment for cardiovascular events in 
many clinical settings, but the added value in atrial fibrillation patients has not been described.
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transient ischemic attack).3 Recently, cardiac troponin, a sen-
sitive indicator of myocardial damage,4,5 was identified as an 
independent marker of increased risk of stroke, other cardio-
vascular events, and mortality in patients with AF by the use 
of contemporary assays.6 The availability of the next genera-
tion of high-sensitivity (hs) troponin assays, which enables the 
detection of very low troponin concentrations with high preci-
sion, has improved the prognostication substantially in several 
patient populations, such as acute coronary syndromes, con-
gestive heart failure, stable atherosclerotic disease, and even in 
apparently healthy elderly subjects.7–14 Knowledge regarding 
the prognostic information gained by high-sensitivity troponin 
assays concerning stroke risk and other cardiovascular events 
in AF is limited. In this biomarker substudy, we assessed the 
associations between high-sensitivity troponin I (hs-TnI) con-
centrations at baseline and clinical outcomes after adjusting 
for established cardiovascular risk factors in 14 821 patients of 
18 201 within the Apixaban for Reduction in Stroke and Other 
Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) 
trial.15,16 We also compared the prognostic information with 
that of the CHA2DS2VASc score and evaluated the outcomes 
with apixaban in comparison with warfarin in relation to lev-
els of hs-TnI.
Methods
The ARISTOTLE Trial
The details of the ARISTOTLE trial have been published previ-
ously.16 In brief, ARISTOTLE was a double-blind, double-dummy, 
randomized clinical trial that enrolled 18 201 patients with AF and 
at least 1 CHADS2 risk factor for stroke or systemic embolism. 
Patients were randomly assigned to warfarin (n=9081) or apixaban 
(n=9120). The primary end point was stroke or systemic embolism. 
Bleeding was classified according to the International Society on 
Thrombosis and Haemostasis criteria. The present biomarker cohort 
consisted of the first 14 821 included patients with hs-TnI available. 
The ARISTOTLE trial was event driven; participants included in the 
trial after the extension amendment were not included in the prespeci-
fied biomarker study. The median length of follow-up was 1.9 years 
for the participants with hs-TnI available. Approval by the appropri-
ate ethics committees was obtained at all sites. All patients provided 
written informed consent.
End Points and Clinical Risk Classification
The end points in this study included stroke or systemic embolism; 
ischemic stroke and systemic embolism, hemorrhagic stroke, myocar-
dial infarction; all-cause mortality; cardiac death (excluding bleeding 
and other noncardiac causes); International Society on Thrombosis 
and Haemostasis major bleeding; composites included stroke or sys-
temic embolism, total death or cardiac death, and myocardial infarc-
tion. A blinded clinical events committee using prespecified criteria 
adjudicated all end points.16 CHADS2 and CHA2DS2VASc scores 
were calculated for each patient based on the sum of the correspond-
ing risk factors present at randomization. Patients were classified by 
CHADS2 0 to 1, 2, or ≥3 and by CHA2DS2VASc scores according to 0 
to 1, 2, 3, 4, and ≥5. Also major bleeding outcomes were evaluated in 
relation to the HAS-BLED score classified by 0 to 1, 2, or ≥3.
Biochemical Methods
All patients were required to provide plasma samples at randomiza-
tion that were frozen in aliquots and stored at –70°C until analyzed 
centrally. The hs-TnI levels were determined with sandwich immuno-
assays on the ARCHITECT i1000SR (Abbott Diagnostics) according 
to the instructions of the manufacturer. With this assay the analytic 
range is 0.0 to 50 000 ng/L; the limit of detection in the UCR labora-
tory is 1.3 ng/L. The lowest concentration measurable with a coef-
ficient of variation of <20% is 1.6 ng/L, and lowest concentration 
measurable with a coefficient of variation of <10% is 3.3 ng/L; the 
99th percentile upper reference limit for healthy subjects is 23 ng/L.17
Statistical Analyses
These analyses included the 14 821 patients who provided blood sam-
ples for the biomarker study at randomization and also had available 
results of the evaluated biomarkers. Demographics and other baseline 
characteristics were summarized by using frequencies for categorical 
variables and median and 25th and 75th percentiles for continuous 
variables. For tests of differences among groups, the χ2 test was used 
for categorical variables, and the Kruskal-Wallis test was used for 
continuous variables.
Multivariable analysis of variance with natural logarithms of 
 hs-TnI as response variable and categorized baseline characteristics 
as explanatory variables was used to investigate the independent 
effect of each variable. Geometric means, calculated by antilogs of 
the model-adjusted means, were compared.
Efficacy analyses included all randomly assigned patients and 
included all events from randomization until the efficacy cutoff 
date (predefined as January 30, 2011). On-treatment analysis pro-
duced results very similar to the intention-to-treat results reported. 
Bleeding analyses were on treatment, including all randomly 
assigned patients who received at least 1 dose of study drug and 
included all events from receipt of the study drug until 2 days after 
the last dose of the study drug. The incidences of the different 
end points were summarized in relation to randomized treatment, 
quartiles of the hs-TnI levels, and CHA2DS2VASc and HAS-BLED 
scores as outlined above.
The outcome in relation to treatment and hs-TnI group were ana-
lyzed by using a Cox proportional hazards model including treatment 
group, hs-TnI quartile group, and treatment by hs-TnI interaction as 
covariates. The estimated hazard ratios (HRs) were used to assess 
the treatment effect within each of the subgroups, and the signifi-
cances of the biomarker interacting with the effect of treatment were 
judged by the significance of the interaction statistic. The outcomes 
in relation to hs-TnI quartiles were evaluated both in a simple and 
in a multivariable Cox proportional hazards model. The multivari-
able analyses included established risk factors (age [continuous], 
sex, body mass index, smoking status, systolic blood pressure, heart 
rate, AF type, diabetes mellitus, history of symptomatic congestive 
heart failure, previous stroke/systemic embolism/transient isch-
emic attack, hypertension, previous myocardial infarction, previous 
peripheral artery disease/coronary artery bypass grafting/percutane-
ous coronary intervention, treatment at randomization with aspirin, 
angiotensin-converting enzyme inhibitors or angiotensin II recep-
tor blocker, Amiodarone, for the major bleeding end point; history 
of anemia and history of spontaneous or clinical relevant bleeding 
were also included), randomized treatment, region, use of warfa-
rin within 7 days before randomization, use of statin medication 
within 30 days before randomization, and biomarkers (cystatin C 
[a marker of renal function] and N-terminal probrain natriuretic 
peptide, continuous). In addition, a model including randomized 
treatment and CHA2DS2VASc score as covariates was analysed. 
The hazard ratios and 95% confidence intervals, with the use of the 
group with the lowest hs-TnI levels as reference, were reported. The 
assumption of proportional hazards was assessed visually by log-
cumulative hazard plots. We performed likelihood ratio tests to evalu-
ate whether the global model fit improved after the addition of hs-TnI.
The increased discriminative value of hs-TnI was investigated by 
estimating the c-statistics generalized for survival data18 for models 
with and without biomarker and also the continuous (category-free) 
net reclassification improvement index for survival data as described 
by Pencina et al.19 The net reclassification improvement index 
among events and among nonevents, and the total net reclassification 
improvement index, as well, were analyzed.
Kaplan–Meier estimates of the cumulative hazard rate were cal-
culated and plotted. All presented event rates were reported per 
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100 patient-years of follow up. All statistical tests were 2-tailed 
and performed at the 0.05 significance level. There were no adjust-
ments for multiple comparisons. The Statistics section at Uppsala 
Clinical Research Center conducted the statistical analyses. All sta-
tistical analyses were performed using SAS software, version 9.3 
(SAS institute Inc, Cary, NC).
Results
Distribution of hs-TnI
hs-TnI was detectable in 98.46% (14 593) of the patients. The 
hs-TnI distribution showed the following levels: mean, 15.7; 
median, 5.4 (25th percentile 3.3, 75th percentile 10.1) ng/L 
in the total population without any differences between the 
randomized treatment groups. Accordingly, ≈25% had hs-TnI 
levels equal to or below the 10% coefficient of variation con-
centration (3.3 ng/L), 50% had hs-TnI levels >5.4 ng/L, and 
25% had hs-TnI levels >10.1 ng/L. A total of 9.2% was con-
sidered to have elevated levels based on the 99th percentile 
limit of a healthy population (23 ng/L).
Baseline Characteristics
Baseline characteristics and medications according to quar-
tiles of hs-TnI are shown in the Table. The majority of risk 
factors that constitute the CHADS2 and CHA2DS2VASc scores 
were more common in patients with higher hs-TnI levels. 
Accordingly, the accumulated score for both the CHADS2 and 
CHA2DS2VASc models increased with rising hs-TnI, 79.2% 
of patients with hs-TnI >10 ng/L had CHA2DS2VASc >2 in 
contrast to only 58.4% of patients with hs-TnI ≤3.3 ng/L. In 
multivariable analysis renal impairment, congestive heart fail-
ure, male sex, previous vascular disease (stroke, peripheral 
arterial disease, coronary artery disease), permanent or persis-
tent AF, age, diabetes mellitus, and higher body mass index, 
had the strongest independent relations to the hs-TnI levels 
(P<0.001 for all).
Relation of hs-TnI to Stroke or Systemic  
Embolism in AF
There was a total of 397 (1.40%/y) stroke or systemic embo-
lism during the median follow-up of 1.9 years. There was 
a marked increase in annual rates with rising hs-TnI levels. 
In unadjusted analysis, there was a 3-fold increase of stroke 
or systemic embolism in the comparison of patients with 
hs-TnI ≤3.3 ng/L and >10.1 ng/L with annual rates ranging 
from 0.76% to 2.26%, respectively. The association remained 
significant in the adjusted Cox analysis which displayed an 
increased risk with hs-TnI levels >5.4 ng/L (HR, 1.49; 95% 
confidence interval, 1.06–2.09) and approximately doubled 
the hazard with hs-TnI >10.1 ng/L (HR, 1.98; 95% confidence 
interval, 1.42–2.78) (Figure 1).
hs-TnI in Relation to Mortality and  
Cardiovascular Events
A total of 1075 (3.69%/y) all-cause mortality, 547 (1.88%/y) 
cardiac deaths, 150 (0.52%/y) myocardial infarctions, and 
674 (2.61%/y) major bleedings were observed in this sub-
study cohort. Higher hs-TnI levels were strongly and sig-
nificantly associated with a higher rate of all outcome events 
in the adjusted Cox analysis (Figure 1). In regard to cardiac 
mortality, the risk increased gradually by higher hs-TnI lev-
els reaching an adjusted HR of 4.52 (3.05–6.70) in the group 
with hs-TnI >10.1 ng/L versus the group with hs-TnI ≤3.3 
ng/L. Despite the overall low event rates, there was a similar 
association between hs-TnI levels and subsequent myocardial 
infarction with a significantly raised risk by higher hs-TnI and 
adjusted HR 3.42 (1.82–6.42) in the group with hs-TnI >10.1 
ng/L versus the group with hs-TnI ≤3.3 ng/L. The rates of the 
composite of the individual events demonstrated correspond-
ingly strong significant associations with increasing hs-TnI 
levels. Also, the rate of major bleeding displayed a relation-
ship to increased hs-TnI levels, although nongradual, with 
an adjusted HR 1.44 (1.11–1.86) in the group with the high-
est versus lowest quartile hs-TnI levels. As illustrated in the 
Kaplan–Meier plots (Figure 2A through 2C the associations 
between hs-troponin levels at baseline and the risk for subse-
quent events remained stable over time.
There was no significant interaction for any of the outcomes 
in relation to the randomized treatments with the hs-TnI levels 
at baseline (Figure 3). Thus, there were consistent reductions 
in stroke, hemorrhagic stroke, total mortality, composites of 
these events, and major bleeding consistent with the overall 
trial irrespective of hs-TnI levels (all interaction P values of 
>0.40). The randomized treatment groups were therefore com-
bined and adjusted for when the association between  hs-TnI 
levels and the above outcomes in the multivariable analyses 
were evaluated.
Risk Stratification Using hs-TnI in Comparison 
With the CHA2DS2VASc and HAS-BLED Scores
Annual rates of stroke or systemic embolism according 
to hs-TnI levels and CHA2DS2VASc score are illustrated 
in Figure 4A. The rates increased with both increasing 
CHA2DS2VASc score and higher hs-TnI level. Within 
CHA2DS2VASc score 0 to 1 the annual rate of stroke or sys-
temic embolism ranged from 0.16% to 2.36% depending 
on hs-TnI quartiles. Patients with hs-TnI <3.3 ng/L and a 
CHA2DS2VASc score up to 2 had an average annual rate of 
0.35%. The groups with the highest rates, 2.14% to 3.48% 
per year, all had hs-TnI levels >10.1 ng/L. The c-statistic was 
0.629 for a model with CHA2DS2VASc score alone and 0.612 
for a model with hs-TnI alone and increased substantially to 
0.653, by adding hs-TnI to the CHA2DS2VASc score.
In relation to mortality and cardiovascular events, hs-TnI 
levels had a substantially larger impact on outcomes in com-
parison with the CHA2DS2VASc score. For cardiac mortality 
(Figure 2B), increasing hs-TnI level had a stronger association 
with event rates than the CHA2DS2VASc score. A model with 
CHA2DS2VASc score alone yielded a c-statistic of 0.591 
for cardiac mortality, a model with hs-TnI alone yielded a 
c-statistic of 0.719 which increased to 0.731 by adding hs-
TnI to the CHA2DS2VASc score. Accordingly, also for the 
composite of ischemic events and mortality, hs-TnI had a bet-
ter discriminative ability than the CHA2DS2VASc score, with 
c-statistic 0.598 for a model with CHA2DS2VASc score alone, 
0.675 for a model with hs-TnI alone, and increasing to 0.690 by 
adding hs-TnI to the CHA2DS2VASc score. Regarding major 
bleeding there was a consistent increase both with increasing 
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hs-TnI and HAS-BLED score groups (Figure 4C). The c-statistic 
was 0.606 for HAS-BLED score alone, 0.598 for hs-TnI alone, 
and increased to 0.630 by adding hs-TnI to the HAS-BLED score.
Models that included hs-TnI showed better global fit than 
models with only CHA2DS2VASc or HAS-BLED score and 
treatment arm, as evaluated by likelihood ratio tests (all 
Table.  Summary of Demographics and Baseline Characteristics by Groups of hs-TnI Level at Baseline.
hs-TnI level, ng/L
≤3.3 >3.3–5.4 >5.4–10.1 >10.1 P Value
n 3889 3592 3658 3682
Age, median(Q1, Q3) 66.0 (59.0, 73.0) 70.0 (63.0, 76.0) 72.0 (65.0, 77.0) 71.0 (64.0, 77.0) <0.0001
Sex male, n (%) 2346 (60.3) 2188 (60.9) 2422 (66.2) 2572 (69.9) <0.0001
Weight, kg, median (Q1, Q3) 84.0 (71.6, 98.0) 82.0 (70.2, 95.5) 82.0 (70.0, 95.0) 80.0 (68.0, 94.0) <0.0001
Heart rate 75.0 (66, 85) 76.0 (66, 86) 76.0 (66, 85) 75.0 (65, 85) 0.13
Permanent or persistent AF, n (%) 3059 (78.7) 3023 (84.2) 3221 (88.1) 3271 (88.8) <0.0001
AF duration ≥ 2 y, n (%) 2024 (52.0) 1960 (54.6) 1964 (53.7) 1940 (52.7) 0.13
NYHA class, n (%) <0.0001
  I 2438 (62.7) 2048 (57.0) 1806 (49.4) 1478 (40.1)
  II 1213 (31.2) 1277 (35.6) 1439 (39.3) 1551 (42.1)
  III 229 (5.9) 257 (7.2) 388 (10.6) 620 (16.8)
  IV 4 (0.1) 4 (0.1) 16 (0.4) 27 (0.7)
Calculated CrCL, mL/min, median 
(Q1, Q3)
83.3 (66.2, 106.8) 75.8 (59.3, 95.3) 70.2 (53.5, 90.3) 65.5 (49.3, 86.6) <0.0001
CHADS
2 risk factors, n (%)
  CHF or LVEF≤40% 943 (24.2) 1053 (29.3) 1443 (39.4) 1876 (51.0) <0.0001
  Hypertension 3396 (87.3) 3150 (87.7) 3220 (88.0) 3203 (87.0) 0.57
  Age ≥ 75 y 743 (19.1) 1079 (30.0) 1384 (37.8) 1343 (36.5) <0.0001
  Diabetes mellitus 892 (22.9) 766 (21.3) 963 (26.3) 1042 (28.3) <0.0001
  Previous stroke or TIA 612 (15.7) 673 (18.7) 729 (19.9) 773 (21.0) <0.0001
CHA
2DS2VASc risk factors, n (%)
  Age 65–74 y 612 (15.7) 673 (18.7) 729 (19.9) 773 (21.0) <0.0001
  Sex female 1543 (39.7) 1404 (39.1) 1236 (33.8) 1110 (30.1) <0.0001
  Myocardial infarction 256 (6.6) 348 (9.7) 571 (15.6) 724 (19.7) <0.0001
  Previous PCI/CABG 436 (11.2) 536 (14.9) 720 (19.7) 812 (22.1) <0.0001
  Peripheral artery disease 106 (2.7) 154 (4.3) 209 (5.7) 253 (6.9) <0.0001
CHADS
2, n (%)
  CHADS
2 ≤1 1773 (45.6) 1345 (37.4) 1029 (28.1) 879 (23.9) <0.0001
  CHADS
2 =2 1342 (34.5) 1305 (36.3) 1348 (36.9) 1350 (36.7)
  CHADS
2 ≥3 774 (19.9) 942 (26.2) 1281 (35.0) 1453 (39.5)
CHA
2DS2VASc, n (%)
  CHA
2DS2VASc ≤1 564 (14.5) 296 (8.2) 221 (6.0) 210 (5.7) <0.0001
  CHA
2DS2VASc =2 1051 (27.0) 833 (23.2) 639 (17.5) 558 (15.2)
  CHA
2DS2VASc =3 1043 (26.8) 952 (26.5) 914 (25.0) 934 (25.4)
  CHA
2DS2VASc =4 712 (18.3) 809 (22.5) 889 (24.3) 883 (24.0)
  CHA
2DS2VASc ≥5 519 (13.3) 702 (19.5) 995 (27.2) 1097 (29.8)
Medications at randomization, n (%)
  Aspirin 1132 (29.1) 1035 (28.8) 1181 (32.3) 1232 (33.5) <0.0001
  Warfarin 2199 (56.5) 1979 (55.1) 1954 (53.4) 1838 (49.9) <0.0001
  ACE inhibitor or ARB 2530 (65.1) 2477 (69.0) 2678 (73.2) 2805 (76.2) <0.0001
  Calcium channel blocker 1306 (33.6) 1135 (31.6) 1073 (29.3) 1008 (27.4) 0.0049
  β-Blocker 2587 (66.5) 2261 (62.9) 2273 (62.1) 2244 (60.9) <0.0001
  Digoxin 830 (21.3) 1018 (28.3) 1367 (37.4) 1595 (43.3) <0.0001
ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass graft; CHF, congestive heart 
failure; CrCL, creatinine clearance; hs-TnI, high-sensitivity troponin I; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PCI, percutaneous 
coronary intervention; Q, quartile; and TIA, transient ischemic attack.
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P<0.0001). Moreover, the addition of hs-TnI also improved 
the discrimination in models incorporating all variables used 
in the adjusted Cox model for all outcomes (results not shown).
The improvement in risk prediction by adding hs-TnI to 
a model with a CHA2DS2VASc score as measured by the 
continuous net reclassification improvement index (95% 
confidence interval) was 22% (10%–40%) for stroke or sys-
temic embolism and 63% (54%–72%) for cardiac death. For 
stroke or systemic embolism events, the amount of correct 
reclassification was greater among non-event patients (con-
tributing 17%), and, for cardiac death, the amount of correct 
reclassification was greater among the event patients (con-
tributing 46%).
Discussion
The major findings of this study were that by using high- 
sensitivity assays troponin I was detectable in 98.5% and ele-
vated in 9.2% of the patients with nonvalvular AF and at least 
1 risk factor for stroke. The relation between hs-TnI and stroke 
or systemic embolic events, cardiac and total death, and myo-
cardial infarction was gradual and remained highly significant 
in adjusted analysis. hs-TnI measurements improved risk 
stratification and risk prediction beyond clinically established 
models such as the CHA2DS2VASc score.
The present results support the independent prognos-
tic value of troponin I levels concerning the risk of stroke, 
mortality, composite ischemic events, and major bleeding in 
patients with AF as recently shown from the Randomized 
Evaluation of Long-Term Anticoagulation Therapy (RE-LY) 
trial.6 In the RE-LY biomarker study, troponin I was mea-
sured in 6189 patients with the use of a contemporary assay 
(Access AccuTnI assay, Beckman Coulter). High-sensitivity 
troponin assays enable the detection of even lower levels of 
troponin I and improvements in the measurement accuracy, 
as well. By using the Beckman Access AccuTnI assay, 57% 
of the AF patients in RE-LY were shown to have detectable 
troponin I, and 8% were classified as having troponin I above 
the 99th percentile, in comparison with 98.5% with detectable 
and 9.2% above the 99th percentile with the current Abbott 
ARCHITECT hs-TnI assay in the present study. The consider-
ably larger number of patients (n=14 821) and the more sensi-
tive troponin assay in the present study in comparison with 
1                                                            3                            5                 7
Lower risk             Higher risk
Stroke/Systemic embolism
≤3.3
>3.3-5.4
>5.4 - 10.1
>10.1
Ischemic or unspecified stroke
≤3.3
>3.3-5.4
>5.4 - 10.1
>10.1
Hemorrhagic stroke
≤3.3
>3.3-5.4
>5.4 - 10.1
>10.1
Death
≤3.3
>3.3-5.4
>5.4 - 10.1
>10.1
Cardiac death
≤3.3
>3.3-5.4
>5.4 - 10.1
>10.1
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Figure 1. Association between hs-troponin I level at baseline and outcomes. Cox proportional hazards model adjusted for established 
risk factors (age, sex, body mass index, smoking status, systolic blood pressure, heart rate, AF type, diabetes mellitus, heart failure, 
previous stroke/systemic embolism/TIA, hypertension, previous myocardial infarction, previous peripheral artery disease/CABG/PCI, 
treatment at randomization with aspirin, ACE inhibitors or ARB, Amiodarone, for the major bleeding end point; history of anemia and 
history of spontaneous or clinically relevant bleeding were also included), randomized treatment, region, use of warfarin within 7 days 
before randomization, use of statin medication within 30 days before randomization score, and biomarkers (cystatin C and NT-proBNP).
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the RE-LY (n=6189) biomarker study demonstrated a greater 
discriminatory power of the hs-TnI than conventional TnI lev-
els concerning all outcome events. In addition, there was a 
larger additive value in the comparison and combination with 
the CHA2DS2VASc score. By adding information of hs-TnI to 
the CHA2DS2VASc risk score identification of patients at both 
lower and higher risk of stroke was improved in comparison 
with either information alone. A substantially lower risk was 
displayed in those having both a low hs-TnI level (≤3.3 ng/L) 
and a low CHA2DS2VASc score (≤2). Further, the determina-
tion of hs-TnI among patients with a CHA2DS2VASc score 
≤2 identified patients with annual rates of stroke similar to 
patients with CHA2DS2VASc scores ≥3. The hs-TnI informa-
tion therefore adds clinically important information allowing 
identification of patients that, despite low CHA2DS2VASc 
scores, still are at high risk of stroke. Consequently, the addi-
tion of hs-TnI to the clinical information should improve 
therapeutic decision making concerning the need for oral anti-
coagulation in patients with AF.
The clinical characteristics included in the CHA2DS2VASc 
risk score have been based on their relations to the risk of 
stroke but not to the risk of other adverse events in AF patients. 
This study clearly showed that, concerning other outcomes 
such as cardiac mortality and myocardial infarction, hs-TnI 
levels alone provided better prognostic information than the 
CHA2DS2VASc risk score. AF is a well-established risk factor 
not only for stroke, but also for increased mortality.1 So far, 
risk stratification and selection of treatment in AF is mainly 
A B
C
Figure 2. Cumulative hazard rate for the primary outcome (stroke or systemic embolism) (A), cardiac death (B), and major bleeding (C) by 
levels of hs-troponin I level at baseline. hs indicates high sensitivity; and SEE, systemic embolism.
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focused on primary or secondary stroke prevention. However, 
in an anticoagulated AF population, such as in the RE-LY 
and ARISTOTLE trial, the total numbers and annual rates of 
death are more than double as common as events of stroke or 
systemic embolism.15,20 Our study clearly demonstrated the 
powerful risk prediction obtained with hs-TnI measurements 
in an AF population concerning mortality, both indepen-
dently and in comparison with CHA2DS2VASc. Accordingly 
hs-TnI provides a novel tool for identification of AF patients 
at increased risk of both stroke and death and may therefore 
be useful for selecting patients not only for anticoagulation, 
but also for other treatment measures to improve survival in 
AF patients.
Cardiac troponin is established as a sensitive indicator of 
myocardial damage.4,5 By using hs assays, even very low 
levels of cardiac troponin become measurable. This has led 
to substantial improvements in the detection of the marker 
and also in regard to risk stratification in patients with acute 
and chronic coronary diseases, in patients with congestive 
heart failure, and even in healthy elderly subjects.7,8,10–13 The 
underlying mechanisms for this independent relationship are 
probably multifactorial because the level of hs-troponin is 
related to aging and tissue vulnerability, myocardial necro-
sis and apoptosis, myocardial stress, eg, due to increased 
or variable heart rates, myocardial dysfunction with varia-
tions in atrial and ventricular volume and pressure load, and 
potential episodes of myocardial ischemia.21–25 The detection 
of cardiac troponin in serum in patients with stable coronary 
artery disease or even apparently healthy individuals have 
contributed to the proposals of alternative mechanisms for 
low-level troponin release in contrast to myocyte necrosis 
as seen in acute coronary syndromes. Mechanisms such as 
increased physiological myocyte turnover, cellular release, 
and reversible increase in cell wall permeability to cardiac 
troponins or troponin fragments have been proposed.26,27 
In the setting of AF, there may also be an association with 
underlying inflammatory and fibrotic processes, including 
endothelial dysfunction contributing to the perpetuation of 
the arrhythmia, to a hypercoagulable state, and to the risk 
of thromboembolism.28–31 However, even without a complete 
understanding of the underlying mechanisms for elevation 
of hs-troponin in AF, its incremental information on the risk 
for cardiovascular events should make it useful for improved 
risk assessment in AF.
Limitations
The present findings derived from a clinical trial population 
with AF and at least 1 risk factor for stroke and may therefore 
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Figure 3. Efficacy of apixaban relative warfarin in relation to hs-troponin I level at baseline. Cox proportional hazards model with 
biomarker level, treatment, and interaction between treatment and biomarker level as covariates. CI indicates confidence interval; HR, 
hazard ratio; and hs, high sensitivity. 
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not be immediately extrapolated to the general AF popula-
tion. The study design does not permit final conclusions about 
the optimal cutoff value of hs-TnI as a decisive tool to select 
patients for different antithrombotic strategies, because all 
study participants received oral anticoagulants.
Conclusion
In patients with AF, hs-TnI is detectable in 98.5% and ele-
vated in 9.2%. The relations between hs-TnI and the risk of 
stroke, myocardial infarction, cardiac and total death, and 
major bleeding were both gradual and independent. The addi-
tion of hs-TnI to clinical risk stratification models for stroke, 
such as the CHA2DS2VASc risk score, allows an improved 
risk assessment and safer identification of patients at very 
low risk and higher risk not detected with the CHA2DS2VASc 
score. Concerning cardiac mortality and other ischemic events 
hs-TnI alone carries more prognostic information than the 
CHA2DS2VASc score. The benefits of apixaban as compared 
with warfarin were consistent regardless of the  hs-TnI levels.
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CLINICAL PERSPECTIVE
Troponin is a widely available biomarker for the diagnosis and prognostication of cardiac diseases. By using high-sensitivity 
assays, we demonstrated that cardiac troponin I was detectable in almost all (98.5%) patients and elevated in 9.3% of patients 
with atrial fibrillation. Determination of troponin levels with a high-sensitivity assay provided incremental discriminative 
information to the currently used CHA2DS2-VASc and HAS-BLED risk scores. Beyond clinical risk factors, an elevated level 
of troponin I identified patients with a doubled risk for stroke or systemic embolism and an up to 4.5-fold increased risk of 
vascular death. Troponin I measurements improved risk prediction substantially in patients with atrial fibrillation beyond 
currently used clinical risk scores. The availability of the cardiac troponin analysis is widespread and easily accessible and 
makes it a very attractive candidate for use to improve the prognostication of patients with atrial fibrillation in addition to the 
currently recommended clinical risk stratification models.
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